Novartis will acquire Regulus Therapeutics for up to $1.7B, boosting its kidney drug pipeline with lead candidate farabursen.

Novartis has agreed to acquire US-based Regulus Therapeutics and its oligonucleotide, farabursen, to bolster its renal ...

Compare Dialysis Centers examined CDC data and other sources to explore kidney disease risk factors and why the condition has ...

Regulus Therapeutics will be acquired by Novartis AG for $7 per share in cash. Click here for more information on RGLS ...

Novartis to buy Regulus for $0.8 billion upfront with potential for $1.7B total based on ADPKD drug milestone; deal set to ...

Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental ...

Woman baffled by painful periods had huge ovarian cyst filled with hair and teeth - Valentina Milanova was told she might ...

But maybe Edgar to start with you and with your expertise in the condition of autosomal dominant polycystic kidney disease, ...

People with diseases caused by rare mutations have fewer options and poorer prospects than other patients despite rapid ...

A physical therapist was shocked to learn that for her, some of her crucial organs had an expiration date. With proactive ...

Polycystic kidney disease (PKD) is a genetic disorder whereby a large number of cysts develop primarily within the kidneys, but also in other organs. PKD can be autosomal dominant (one mutated ...

Oral infections are more likely to occur in people with chronic kidney disease and are more likely to become a significant problem. Proper dental care also benefits people on dialysis or those ...